{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:56:33Z","timestamp":1793775393594,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.wneu.2023.05.097","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:00:35Z","timestamp":1685592035000},"page":"e543-e547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Should Redo Surgery be Offered to Patients with Relapsed Glioblastoma? - Outcome Analyses of a Single Institution Comparative Cohort Study"],"prefix":"10.1016","volume":"176","author":[{"given":"Mohamed","family":"Eltoukhy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswapathi","family":"Kandula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibu","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraj","family":"Giridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2023.05.097_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ejca.2014.12.014","article-title":"Glioblastoma in England: 2007\u20132011","volume":"51","author":"Brodbelt","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2023.05.097_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2023.05.097_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre-and post-2005: a systematic review and meta-analysis","volume":"10","author":"Poon","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.wneu.2023.05.097_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"The lancet oncology"},{"key":"10.1016\/j.wneu.2023.05.097_bib5","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/jco.2015.33.15_suppl.2000","article-title":"Tumor treating fields (TTFields): a novel treatment modality added to standard chemo-and radiotherapy in newly diagnosed glioblastoma\u2014first report of the full dataset of the EF14 randomized phase III trial","volume":"33","author":"Stupp","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-016-0975-5","article-title":"Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review","volume":"14","author":"Ashby","year":"2016","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA\u201309): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2023.05.097_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/2278-330X.175953","article-title":"Recurrent glioblastoma: where we stand","volume":"4","author":"Roy","year":"2015","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.wneu.2023.05.097_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.wneu.2019.03.250","article-title":"Survival benefit of maximal resection for glioblastoma reoperation in the temozolomide era: a meta-analysis","volume":"127","author":"Lu","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2023.05.097_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","article-title":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma","volume":"17","author":"Field","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4137\/CMO.S7232","article-title":"Bevacizumab for the treatment of recurrent glioblastoma","volume":"5","author":"Chamberlain","year":"2011","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan\u2013vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"28","author":"Batchelor","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nature Med"},{"key":"10.1016\/j.wneu.2023.05.097_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/cns-2016-0049","article-title":"Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial","volume":"6","author":"Kesari","year":"2017","journal-title":"CNS Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noy200","article-title":"A\u00a0randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-017-2731-2","article-title":"Outcomes after second surgery for recurrent glioblastoma: a retrospective case\u2013control study","volume":"137","author":"Wann","year":"2018","journal-title":"J\u00a0Neurooncology"},{"key":"10.1016\/j.wneu.2023.05.097_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11060-017-2573-y","article-title":"Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?","volume":"135","author":"Zanello","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2023.05.097_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jocn.2015.05.047","article-title":"Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era","volume":"24","author":"Ortega","year":"2016","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2023.05.097_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clineuro.2016.01.010","article-title":"Second surgery for recurrent glioblastoma: a concise overview of the current literature","volume":"142","author":"Montemurro","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.wneu.2023.05.097_bib22","first-page":"1743","article-title":"The effect of re-operation on survival in patients with recurrent glioblastoma","volume":"35","author":"Franceschi","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.wneu.2023.05.097_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.wneu.2015.03.018","article-title":"Efficacy of surgery and further treatment of progressive glioblastoma","volume":"84","author":"Woernle","year":"2015","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2023.05.097_bib24","first-page":"846","article-title":"An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity","volume":"120","author":"Oppenlander","year":"2014","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2023.05.097_bib25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.clineuro.2012.08.030","article-title":"The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma","volume":"115","author":"De Bonis","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.wneu.2023.05.097_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0404.2010.01350.x","article-title":"Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme","volume":"122","author":"Helseth","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.wneu.2023.05.097_bib27","first-page":"117","article-title":"Efficacy of clinical prognostic factors on survival in patients with glioblastoma","volume":"20","author":"Tugcu","year":"2010","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.wneu.2023.05.097_bib28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jocn.2009.02.036","article-title":"Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China","volume":"16","author":"Ma","year":"2009","journal-title":"J\u00a0Clin Neurosci"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875023007295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875023007295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:23:20Z","timestamp":1761816200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875023007295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S1878875023007295"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2023.05.097","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should Redo Surgery be Offered to Patients with Relapsed Glioblastoma? - Outcome Analyses of a Single Institution Comparative Cohort Study","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2023.05.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}